OBX-319 — Regulatory Dossier: Reader's Guide

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📚

What this is

A walk-through of a complete, submission-shaped regulatory dossier for a virtual drug — OBX-319, an anti-CD19 × anti-CD20 B-cell-depleting bispecific antibody for moderate-to-severe systemic lupus erythematosus (SLE). Generated end-to-end by the CTAP skill from one study definition, then agent-enriched to submission depth: every clinical figure comes from one simulated Phase 3 trial (SLEDAI-2K endpoint, near-complete CD19 B-cell depletion), and each linked article opens with a plain-language guide before the live document. A portfolio demonstration, not a real submission.

🗺️

How a submission is organized (the CTD)

Marketing applications worldwide share the ICH Common Technical Document (CTD), a five-module structure. Module 1 is region-specific admin and labeling; Module 2 is the high-level summaries a reviewer reads first; Module 3 is quality / manufacturing (CMC); Module 4 is the animal (nonclinical) studies; Module 5 is the human clinical studies and data. The Trial Master File, program-management, and quality documents are the operational records that stand behind the trial.

Every document, explained

Module 1 — Regional & Administrative

Module 1 (EU) — Application Form & Cover Letter (OBX-319) — Module 1 (EU) — Application Form & Cover Letter (OBX-319)
Module 1 (EU) — IMPD Summary (OBX-319) — Module 1 (EU) — IMPD Summary (OBX-319)
Module 1 (EU) — Summary of Product Characteristics (OBX-319) — Module 1 (EU) — Summary of Product Characteristics (OBX-319)
Module 1 (EU) — Risk Management Plan (OBX-319) — Module 1 (EU) — Risk Management Plan (OBX-319)
Module 1 — Environmental Assessment / Categorical Exclusion (OBX-319) — Module 1 — Environmental Assessment / Categorical Exclusion (OBX-319)
Module 1 (US) — Form 356h & Cover Letter (OBX-319) — Module 1 (US) — Form 356h & Cover Letter (OBX-319)
Module 1 (US) — Administrative Forms (OBX-319) — Module 1 (US) — Administrative Forms (OBX-319)
Module 1 (US) — Application Summary (OBX-319) — Module 1 (US) — Application Summary (OBX-319)
Module 1 — Container/Carton/Patient Labeling (OBX-319) — Module 1 — Container/Carton/Patient Labeling (OBX-319)
Module 1 (US) — Administrative & US Prescribing Information (OBX-319) — Module 1 (US) — Administrative & US Prescribing Information (OBX-319)
Module 1 (US) — REMS Assessment (OBX-319) — Module 1 (US) — REMS Assessment (OBX-319)
Module 1.0 — Administrative Documents Index (OBX-319) — Module 1.0 — Administrative Documents Index (OBX-319)
Expedited Program Requests (OBX-319) — Expedited Program Requests (OBX-319)
End-of-Phase-2 Briefing Book (OBX-319) — End-of-Phase-2 Briefing Book (OBX-319)
Pre-IND Briefing Book (OBX-319) — Pre-IND Briefing Book (OBX-319)
Pre-NDA/BLA Briefing Book (OBX-319) — Pre-NDA/BLA Briefing Book (OBX-319)
Module 1 (KR) — IND / Application Summary (OBX-319) — Module 1 (KR) — IND / Application Summary (OBX-319)
Module 1 (KR) — Application Form & Cover Letter (OBX-319) — Module 1 (KR) — Application Form & Cover Letter (OBX-319)
Module 1 (KR) — Administrative & Label (OBX-319) — Module 1 (KR) — Administrative & Label (OBX-319)
Module 1 (KR) — Risk Management Plan (OBX-319) — Module 1 (KR) — Risk Management Plan (OBX-319)
Module 1 — Pediatric Study Plan (PSP/PIP) (OBX-319) — Module 1 — Pediatric Study Plan (PSP/PIP) (OBX-319)
Development Safety Update Report (OBX-319) — Development Safety Update Report (OBX-319)
Periodic Benefit-Risk Evaluation Report (OBX-319) — Periodic Benefit-Risk Evaluation Report (OBX-319)
Signal Management Plan (OBX-319) — Signal Management Plan (OBX-319)

Module 2 — CTD Summaries & Overviews

Module 2.1 — CTD Table of Contents (OBX-319) — Module 2.1 — CTD Table of Contents (OBX-319)
Module 2.2 — Introduction (OBX-319) — Module 2.2 — Introduction (OBX-319)
Module 2.3 — Quality Overall Summary (OBX-319) — Module 2.3 — Quality Overall Summary (OBX-319)
Module 2.4 — Nonclinical Overview (OBX-319) — Module 2.4 — Nonclinical Overview (OBX-319)
Module 2.5.6 — Benefit–Risk Assessment (OBX-319) — Module 2.5.6 — Benefit–Risk Assessment (OBX-319)
Module 2.5 — Clinical Overview (OBX-319) — Module 2.5 — Clinical Overview (OBX-319)
Module 2.6 — Nonclinical Summaries (OBX-319) — Module 2.6 — Nonclinical Summaries (OBX-319)
Module 2.7.1 — Summary of Biopharmaceutic Studies (OBX-319) — Module 2.7.1 — Summary of Biopharmaceutic Studies (OBX-319)
Module 2.7.2 — Summary of Clinical Pharmacology Studies (OBX-319) — Module 2.7.2 — Summary of Clinical Pharmacology Studies (OBX-319)
Module 2.7.3 — Summary of Clinical Efficacy (OBX-319) — Module 2.7.3 — Summary of Clinical Efficacy (OBX-319)
Module 2.7.4 — Summary of Clinical Safety (OBX-319) — Module 2.7.4 — Summary of Clinical Safety (OBX-319)
Module 2.7.5 — Literature References (OBX-319) — Module 2.7.5 — Literature References (OBX-319)
Module 2.7.6 — Synopses of Individual Studies (OBX-319) — Module 2.7.6 — Synopses of Individual Studies (OBX-319)

Module 3 — Quality (CMC)

Module 3 — Analytical Methods Validation (OBX-319) — Module 3 — Analytical Methods Validation (OBX-319)
Module 3 — Appendices & Regional (3.2.A/3.2.R) (OBX-319) — Module 3 — Appendices & Regional (3.2.A/3.2.R) (OBX-319)
Module 3 — Control Strategy (OBX-319) — Module 3 — Control Strategy (OBX-319)
Module 3 — Device & Combination Product (OBX-319) — Module 3 — Device & Combination Product (OBX-319)
Module 3.2.P — Drug Product (OBX-319) — Module 3.2.P — Drug Product (OBX-319)
Module 3 — Process Validation (OBX-319) — Module 3 — Process Validation (OBX-319)
Module 3 — QTPP & CQA (OBX-319) — Module 3 — QTPP & CQA (OBX-319)
Module 3.2.S — Drug Substance (OBX-319) — Module 3.2.S — Drug Substance (OBX-319)
Module 3 — Stability Summary (OBX-319) — Module 3 — Stability Summary (OBX-319)

Module 4 — Nonclinical (Animal) Study Reports

Module 4.2.1 — Pharmacology (OBX-319) — Module 4.2.1 — Pharmacology (OBX-319)
Module 4.2.2 — Pharmacokinetics (OBX-319) — Module 4.2.2 — Pharmacokinetics (OBX-319)
Module 4.2.3 — Toxicology (OBX-319) — Module 4.2.3 — Toxicology (OBX-319)
Module 4.3 — Literature References (OBX-319) — Module 4.3 — Literature References (OBX-319)
SEND / Nonclinical Data Reviewer's Guide (OBX-319) — SEND / Nonclinical Data Reviewer's Guide (OBX-319)

Module 5 — Clinical Study Reports & Data

Bioanalytical Method Validation (OBX-319) — Bioanalytical Method Validation (OBX-319)
Biopharmaceutic Study Reports (OBX-319) — Biopharmaceutic Study Reports (OBX-319)
Human Pharmacokinetic Study Report (OBX-319) — Human Pharmacokinetic Study Report (OBX-319)
Human PD & QT Study Reports (OBX-319) — Human PD & QT Study Reports (OBX-319)
Immunogenicity Summary Report (OBX-319) — Immunogenicity Summary Report (OBX-319)
Annotated Case Report Form (OBX319-301) — Annotated Case Report Form (OBX319-301)
Blank Case Report Form (OBX319-301) — Blank Case Report Form (OBX319-301)
SAD Study Synopsis (OBX-319) — SAD Study Synopsis (OBX-319)
MAD Study Synopsis (OBX-319) — MAD Study Synopsis (OBX-319)
Phase 2 Study Synopsis (OBX-319) — Phase 2 Study Synopsis (OBX-319)
Patient Narratives (OBX319-301) — Patient Narratives (OBX319-301)
Clinical Study Report (OBX319-301) — Clinical Study Report (OBX319-301)
Clinical Study Report Synopsis (OBX-319) — Clinical Study Report Synopsis (OBX-319)
Analysis Results Metadata (OBX319-301) — Analysis Results Metadata (OBX319-301)
Analysis Data Reviewer's Guide (OBX319-301) — Analysis Data Reviewer's Guide (OBX319-301)
Study Data Reviewer's Guide (OBX319-301) — Study Data Reviewer's Guide (OBX319-301)
CDISC Conformance Validation Report — OBX319-301 — CDISC Conformance Validation Report — OBX319-301
Investigator's Brochure (OBX-319) — Investigator's Brochure (OBX-319)
Integrated Summary of Efficacy (OBX-319) — Integrated Summary of Efficacy (OBX-319)
Integrated Summary of Safety (OBX-319) — Integrated Summary of Safety (OBX-319)
Tabular Listing of Clinical Studies (OBX-319) — Tabular Listing of Clinical Studies (OBX-319)
Module 5.4 — Literature References (OBX-319) — Module 5.4 — Literature References (OBX-319)
Protocol Synopsis (OBX-319) — Protocol Synopsis (OBX-319)
ADaM Dataset Specification (OBX319-301) — ADaM Dataset Specification (OBX319-301)
Statistical Analysis Plan (OBX-319) — Statistical Analysis Plan (OBX-319)
Statistical Analysis Report (OBX319-301) — Statistical Analysis Report (OBX319-301)
TLF Shells (OBX319-301) — TLF Shells (OBX319-301)

Trial Master File — how the trial is run

Informed Consent Form (OBX319-301) — Informed Consent Form (OBX319-301)
Data Management Plan (OBX319-301) — Data Management Plan (OBX319-301)
Clinical Monitoring Plan (OBX319-301) — Clinical Monitoring Plan (OBX319-301)
Data Safety Monitoring Board Charter (OBX319-301) — Data Safety Monitoring Board Charter (OBX319-301)
Safety Management Plan (OBX319-301) — Safety Management Plan (OBX319-301)
DSMB Meeting Minutes (OBX319-301) — DSMB Meeting Minutes (OBX319-301)
Pharmacy Manual (OBX319-301) — Pharmacy Manual (OBX319-301)
Laboratory Manual (OBX319-301) — Laboratory Manual (OBX319-301)
Randomization & IWRS Plan (OBX319-301) — Randomization & IWRS Plan (OBX319-301)
Clinical Trial Agreement & IRB/IEC Approvals (OBX319-301) — Clinical Trial Agreement & IRB/IEC Approvals (OBX319-301)

Program Management

Project Charter (OBX-319) — Project Charter (OBX-319)
Governance & RACI (OBX-319) — Governance & RACI (OBX-319)
Program Budget & Cost Model (OBX-319) — Program Budget & Cost Model (OBX-319)
Program Risk Register (OBX-319) — Program Risk Register (OBX-319)
Vendor / CRO Management (OBX-319) — Vendor / CRO Management (OBX-319)
Clinical Development Plan (OBX-319) — Clinical Development Plan (OBX-319)

Quality

Quality Management Plan (OBX319-301) — Quality Management Plan (OBX319-301)
Protocol Deviation Log (OBX319-301) — Protocol Deviation Log (OBX319-301)
Issue / CAPA Log (OBX319-301) — Issue / CAPA Log (OBX319-301)
Decision Log (OBX319-301) — Decision Log (OBX319-301)

Portfolio project. The drug, sponsor, and data are fictional; the standards, methods, and document structure are real.